Latest news with #KrishnaElla
New Indian Express
26-06-2025
- Health
- New Indian Express
Bharat Biotech to slash malaria vaccine prices by 2028
HYDERABAD: Bharat Biotech International Limited (BBIL) and GSK plc on Wednesday announced a price reduction on the world's first malaria vaccine, RTS.S. The vaccine developed by GSK, PATH and partners will have a price reduction of $5 progressively by 2028. The price reduction is driven by process improvements, expanded production capacity, cost- effective manufacturing. The announcement was made by Bharat Biotech and GSK as a part of Gavi, the Vaccine Alliance, for its next replenishment phase (Gavi 6.0, 2026-2030) by both companies. Dr. Krishna Ella, Executive Chairman of Bharat Biotech International Limited said: 'This pledge to Gavi 6.0 is more than a pricing announcement. It is a commitment to global equity and innovation. Through this historic announcement, we aim to change the course of malaria burden for millions of children and families. For us, this is more than a cooperation, By joining forces with GSK, and working closely with Gavi, and the WHO, we are taking a real step toward closing the gap between vaccine supply and the urgent needs of children at risk of malaria.
United News of India
25-06-2025
- Health
- United News of India
World's first kids' malaria vaccine price to be less than USD 5 by 2028
Hyderabad, June 25 (UNI) Bharat Biotech International Limited (BBIL) and GSK plc, a Global Pharma Company, today announced their commitment to Gavi, the Vaccine Alliance (Gavi), in the continued roll out of the world's first malaria vaccine. Bharat Biotech will be reducing the price of world first malaria vaccine 'RTS.S, developed by GSK, PATH and partners, by more than half, to less than $5 progressively by 2028. This price reduction is driven by process improvements, expanded production capacity, cost- effective manufacturing, and minimal profit margins, Hyderabad based vaccine maker BBIL said in a release here. The announcement forms part of pledges to Gavi for its next replenishment phase (Gavi 6.0, 2026-2030) by both companies. RTS,S was the first malaria vaccine recommended by the World Health Organisation (WHO) in 2021. Since then, GSK has made significant investments to enhance production capacity and efficiency, and to undertake the planned technology transfer to Bharat Biotech. In parallel, Bharat Biotech has invested over $200 million in new, higher- output manufacturing facilities, product development and technology transfers. These enhancements have enabled a phased reduction in the price of the malaria vaccine, starting immediately and fully realised by 2028, when the transfer of production between the two companies is complete. Through Gavi support, RTS,S expected to be rolled out in 12 endemic countries in Africa through routine immunisation programmes by end of 2025 This has only been possible through the critical work that GSK has undertaken with Bharat Biotech, PATH, together with the WHO, implementing countries, MedAccess and Gavi, to help deliver access to life-saving malaria prevention for children in endemic countries in Africa. BBIL Executive Chairman Dr. Krishna Ella, said: "Through this historic announcement, we aim to change the course of malaria burden for millions of children and families. By joining forces with GSK, and working closely with Gavi, and the WHO, we are taking a real step toward closing the gap between vaccine supply and the urgent needs of children at risk of malaria'. In a recent evaluation of impact by the WHO of the Malaria Vaccine Implementation Programme (MVIP) in Ghana, Kenya and Malawi, where over 2 million children received the RTS,S vaccine between 2019 and 2023, the WHO reported a 13 percent reduction in all-cause mortality and a 22 percent reduction in hospitalisations of severe malaria among children age- eligible for vaccination during this period1. When administered seasonally in regions with high malaria transmission, alongside seasonal malaria chemoprevention, the two malaria vaccines recommended by the WHO, have been shown to prevent around 75 percent of malaria episodes. UNI KNR SSP
The Hindu
25-06-2025
- Health
- The Hindu
Bharat Biotech, GSK to cut malaria vaccine price by more than half by 2028
Bharat Biotech International Ltd and GSK plc on Wednesday said they will reduce the price of the world's first malaria vaccine for children 'RTS,S' developed by GSK, PATH and partners, by more than half to less than USD 5 progressively by 2028. Announced as part of their commitment to the Vaccine Alliance (Gavi), the two companies said the price reduction is driven by process improvements, expanded production capacity, cost-effective manufacturing, and minimal profit margins. Lower vaccine cost through collaboration The announcement forms part of pledges to Gavi for its next replenishment phase -- Gavi 6.0, 2026-2030 -- by both companies, they said in a joint statement. "This pledge to Gavi 6.0 is more than a pricing announcement. It is a commitment to global equity, innovation, and collaboration. Through this historic announcement, we aim to change the course of malaria burden for millions of children and families," Bharat Biotech International Ltd (BBIL) Executive Chairman Krishna Ella said. Further, he said, "By joining forces with GSK, and working closely with Gavi, and the WHO, we are taking a real step toward closing the gap between vaccine supply and the urgent needs of children at risk of malaria." GSK Chief Global Health Officer Thomas Breuer said the company had partnered with Bharat Biotech in 2021 with a common goal of finding a sustainable solution to get ahead of malaria. "Today, we announce GSK's contribution to the long-term price ambition of the world's first malaria vaccine, a key milestone achieved through collaboration with Bharat Biotech and partners from Gavi, PATH and the WHO," he said. Breuer added, "This demonstrates our commitment to changing the trajectory of infectious diseases like malaria, making a difference in the lives of children and families across Africa." The GSK team has worked hand in hand with Bharat Biotech to transfer the vaccine manufacturing technology while simultaneously implementing crucial improvements in manufacturing efficiencies, resulting in the latest pledge to the Gavi replenishment, he noted. Boosting malaria immunisation drive With Gavi's support, 12 endemic countries in Africa will be introduced to RTS,S through routine immunisation programmes by the end of 2025. RTS,S was the first malaria vaccine recommended by the World Health Organization (WHO) in 2021. Since then, GSK has made significant investments to enhance production capacity and efficiency and undertake the planned technology transfer to Bharat Biotech, the statement said. In parallel, Bharat Biotech has invested over USD 200 million in new, higher-output manufacturing facilities, product development and technology transfers. "These enhancements have enabled a phased reduction in the price of the malaria vaccine, starting immediately and fully realised by 2028, when the transfer of production between the two companies is complete," it added. Gavi, the Vaccine Alliance CEO Sania Nishtar said, "Our ambition is to protect at least 50 million more children across Africa by the end of 2030, and this collaboration between GSK and Bharat Biotech helps put this goal firmly within reach."
Time of India
25-06-2025
- Business
- Time of India
Bharat Biotech, GSK to slash malaria vax prices to less than $5 per dose by 2028
HYDERABAD: Vaccine maker Bharat Biotech International Ltd and British biopharma giant GSK plc will be slashing the prices of the world's first malaria vaccine – RTS,S or Mosquirix – by over half to less than $5 per dose by 2028 as part of their pledges to Gavi's replenishment process for 2026-2030. Tired of too many ads? go ad free now The proposed price reduction will be driven by process improvements, expanded production capacity, cost- effective manufacturing, and minimal profit margins, they said in a joint statement on Wednesday. The vaccine, developed by GSK, global non-profit PATH and partners, was the first malaria vaccine to be recommended by the World Health Organization (WHO) in 2021. The same year Bharat Biotech entered into a product transfer agreement with them to manufacture the vaccine in India. As part of the pact, GSK will be transferring the technology for the antigen part of the vaccine to Bharat Biotech and has also granted a licence on all rights for the vaccine, with Bharat Biotech taking over the complete manufacturing of the vaccine by 2028 and enabling the price reduction to below $5 per dose. GSK said it has made significant investments to enhance production capacity and efficiency, and to undertake the planned technology transfer to Bharat Biotech. Bharat Biotech, on the other hand, has invested over $200 million in setting up new, higher- output manufacturing facilities, product development and technology transfers. 'These enhancements have enabled a phased reduction in the price of the malaria vaccine, starting immediately and fully realised by 2028, when the transfer of production between the two companies is complete,' the joint statement said. Bharat Biotech executive chairman Dr Krishna Ella said the pledge is more than a pricing announcement and is a commitment to global equity, innovation, and collaboration. Tired of too many ads? go ad free now 'By joining forces with GSK, and working closely with Gavi, and the WHO, we are taking a real step toward closing the gap between vaccine supply and the urgent needs of children at risk of malaria.' GSK's chief global health officer Thomas Breuer said his company had partnered with Bharat Biotech in 2021 with a common goal to find a sustainable solution to malaria. 'The GSK team has worked hand in hand with Bharat Biotech to transfer the vaccine manufacturing technology, while simultaneously implementing crucial improvements in manufacturing efficiencies, resulting in today's pledge to the Gavi replenishment,' he said.
The Hindu
25-06-2025
- Health
- The Hindu
Bharat Biotech to begin supplies of GSK's malaria vaccine RTS.S to GAVI in 2026
Bharat Biotech International will start supplying world's first malaria vaccine RTS.S, developed by global biopharma major GSK, to vaccine alliance Gavi from 2026. The supplies form part of pledges by both companies to Gavi for its next replenishment phase (Gavi 6.0, 2026-2030), the Hyderabad-based vaccine maker said on Wednesday, announcing it will also progressively reduce price of the vaccine by more than half to less than $5 by 2028. Process improvements, expanded production capacity, cost-effective manufacturing and minimal profit margins will be factors driving down the price, it said. RTS,S was the first malaria vaccine recommended by the World Health Organization (WHO) in 2021. Technology transfer Since then, GSK has made significant investments to enhance production capacity and efficiency and to undertake the planned technology transfer to Bharat Biotech, which in parallel, invested over $200 million in new, higher-output manufacturing facilities, product development and technology transfers. These enhancements have enabled a phased reduction in the price of the malaria vaccine, starting immediately and fully realised by 2028, when the transfer of production between the two companies is complete, it said. With Gavi's support, 12 endemic countries in Africa will introduce RTS,S through routine immunisation programmes by 2025. 'By joining forces with GSK and working closely with Gavi and the WHO, we are taking a real step toward closing the gap between vaccine supply and the urgent needs of children at risk of malaria,' Bharat Biotech Executive Chairman Krishna Ella said. GSK's Chief Global Health Officer Thomas Breuer said 'We partnered with Bharat Biotech in 2021 with a common goal... Today, we announce GSK's contribution to the long-term price ambition of the world's first malaria vaccine, a key milestone achieved through collaboration with Bharat Biotech and partners from Gavi, PATH and the WHO.' The GSK team has worked hand in hand with Bharat Biotech to transfer the vaccine manufacturing technology, while simultaneously implementing crucial improvements in manufacturing efficiencies, resulting in the pledge to the Gavi replenishment, he said. 'Our ambition is to protect at least 50 million more children across Africa by the end of 2030 and this collaboration between GSK and Bharat Biotech helps put this goal firmly within reach,' Gavi CEO Sania Nishtar said.
